Drug
M6620
M6620: highest development phase Phase 1, developed by Merck KGaA. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Merck KGaA
Trials
| Drug | Phase | Indication |
|---|---|---|
| M6620 NCT03704467 | Phase 1 | Ovarian Cancer |
Latest
No recent events.
Follow M6620 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.